<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729505</url>
  </required_header>
  <id_info>
    <org_study_id>mansoura66</org_study_id>
    <nct_id>NCT03729505</nct_id>
  </id_info>
  <brief_title>Impact of Pyloric Injection of Magnesium Sulfate and Lidocaine Mixture on Outcome After Sleeve Gastrectomy</brief_title>
  <official_title>Impact of Pyloric Injection With Magnesium Sulphate and Lidocaine Mixture on Early Postoperative Outcome After Laparoscopic Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting is a common adverse effect after sleeve gastrectomy, mostly
      due to increased intragastric pressure. The present trial aimed to assess the effect of
      pyloric injection of mixture of magnesium sulfate and lidocaine on postoperative gastric
      intraluminal pressure and incidence of nausea and vomiting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">July 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>first 24 hours after surgery</time_frame>
    <description>incidence of postoperative nausea and vomiting as measured by special impact scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Pyloric injection of magnesium sulfate and lidocaine mixture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After sleeve gastrectomy, the pylorus is injected with a mixture of magnesium sulfate and lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyloric injection of saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After sleeve gastrectomy, the pylorus is injected with normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pyloric injection of magnesium sulfate and lidocaine mixture</intervention_name>
    <description>100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus</description>
    <arm_group_label>Pyloric injection of magnesium sulfate and lidocaine mixture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pyloric injection of saline</intervention_name>
    <description>5 ml of normal saline is injected in the pylorus</description>
    <arm_group_label>Pyloric injection of saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that aged between18 and 65 years.

          -  American Society of Anesthesiologists (ASA) class I - III.

          -  Morbidly-obese patients who failed to achieve and maintain a clinically significant
             weight loss through supervised non-surgical methods for at least 6 months.

          -  Surgery was conducted as the first line of treatment in case of patients with BMI ≥ 50
             kg/m2 (super obese).

        Exclusion Criteria:

          -  Obesity secondary to endocrine disorders.

          -  History of any previous bariatric procedure.

          -  Impaired intellectual capacity or major psyciatric disorder.

          -  Sweet eaters who would not adopt a change of postoperative eating habits.

          -  Lack of willingness and motivation to embrace postoperative lifestyle changes.

          -  Substance abuse.

          -  Pregnancy or expected pregnancy in the following 12 to 18 months.

          -  Severe gastroesophageal reflux disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameh H Emile</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura university hospital</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Sameh Emile</investigator_full_name>
    <investigator_title>Lecturer of general surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

